• Completed

NCT00081939: UARK 2003-33, Total Therapy III

Updated: Sep 27

UARK 2003-33, Total Therapy III

Total Therapy 3

Total Therapy 3

The UARK 2003-33, Total Therapy III - There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT):

Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had better outcomes (meaning patients have lived longer and had better responses to treatment) when compared to patients treated with standard chemotherapy. With this new study, Total Therapy III, researchers will take what they have learned from the first two studies and add new treatment strategies to try to improve the outcomes even more, especially for patients with chromosome abnormalities.


Sponsor

University of Arkansas

 

ClinicalTrials.gov Identifier: NCT00081939

A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance

First Posted : April 29, 2004

Click here for details on ClinicalTrials.gov

 

Melphalan

VDTPACE =

Velcade - Brtezomib

Thalidomide

Dexamethasone

Cisplatin

Adriamycin

Cyclophosphamide

Etoposide

 

Drug: Velcade

Drug: Thalidomide

 

Pawlyn C.

High-risk myeloma: a challenge to define and to determine the optimal treatment.

Lancet Haematol. 2021 Jan;8

https://pubmed.ncbi.nlm.nih.gov/33357481/

Våtsveen TK, Sponaas AM, Tian E, Zhang Q, Misund K, Sundan A, Børset M, Waage A, Brede G.

Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.

J Hematol Oncol. 2016 Aug 31;9(1):75.

https://pubmed.ncbi.nlm.nih.gov/27581518/

Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

Blood. 2013 Jun 6

https://pubmed.ncbi.nlm.nih.gov/23603914/

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

Blood. 2013 Mar 7

https://pubmed.ncbi.nlm.nih.gov/23305732/

Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Haematologica. 2013 Jan

https://pubmed.ncbi.nlm.nih.gov/22733020/

Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Haematologica. 2012

https://pubmed.ncbi.nlm.nih.gov/22689675/

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Blood. 2012 Aug

https://pubmed.ncbi.nlm.nih.gov/22674807/

 

Location

United States, Arkansas

Principal Investigator:Bart Barlogie, MD, PhDUAMS







Posts Archive